Primary Prevention of Cardiovascular Disease in Diabetes Mellitus

Journal of the American College of Cardiology

Volumn 70, Issue 7, 2017, Pages 883-893

  Newman, Jonathan D ^a   Schwartzbard, Arthur Z ^a   Weintraub, Howard S ^a   Goldberg, Ira J ^a   Berger, Jeffrey S ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

cardiovascular disease; primary prevention; type 2 diabetes

Indexed keywords

FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL;

ALCOHOL CONSUMPTION; BLOOD PRESSURE REGULATION; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DRUG EFFICACY; FEMALE; HUMAN; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXYGEN CONSUMPTION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; GLOBAL HEALTH; MORBIDITY; PRIMARY PREVENTION; PROCEDURES; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLOBAL HEALTH; HUMANS; MORBIDITY; PRIMARY PREVENTION; RISK FACTORS;

EID: 85028617422     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.07.001     Document Type: Review

References (73)

1. Fox, C.S., Golden, S.H., Anderson, C., et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 132 (2015), 691–718.
2. Ali, M.K., Bullard, K.M., Saaddine, J.B., Cowie, C.C., Imperatore, G., Gregg, E.W., Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med 368 (2013), 1613–1624.
3. Centers for Disease Control and Prevention. Diabetes Report Card. 2014. Available at: https://www.cdc.gov/diabetes/pdfs/library/diabetesreportcard2014.pdf Accessed October 19, 2016.
4. Wang, C.C.L., Hess, C.N., Hiatt, W.R., Goldfine, A.B., Clinical update: cardiovascular disease in diabetes mellitus. Circulation 133 (2016), 2459–2502.
5. Look AHEAD Research Group, Wing, R.R., Bolin, P., Brancati, F.L., et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369 (2013), 145–154.
6. Manson, J.E., Shufelt, C.L., Robins, J.M., The potential for postrandomization confounding in randomized clinical trials. JAMA 315 (2016), 2273–2274.
7. Gaede, P., Vedel, P., Larsen, N., Jensen, G.V.H., Parving, H.-H., Pedersen, O., Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003), 383–393.
8. Gaede, P., Vedel, P., Parving, H.H., Pedersen, O., Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353 (1999), 617–622.
9. Knowler, W.C., Barrett-Connor, E., Fowler, S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002), 393–403.
10. The Diabetes Prevention Program Outcomes Study Research Group, Orchard, T.J., Temprosa, M., Barrett-Connor, E., et al. Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med 30 (2013), 46–55.
11. Chudyk, A., Petrella, R.J., Effects of exercise on cardiovascular risk factors in type 2 diabetes: a meta-analysis. Diabetes Care 34 (2011), 1228–1237.
12. Church, T.S., Blair, S.N., Cocreham, S., et al. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes. JAMA 304 (2010), 2253–2262.
13. American Diabetes Association. Standards of Medical Care in Diabetes–2016. Diabetes Care 39:Suppl 1 (2016), S1–S93.
14. Sacks, F.M., Svetkey, L.P., Vollmer, W.M., et al., DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 344 (2001), 3–10.
15. Estruch, R., Ros, E., Salas-Salvadó, J., et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 368 (2013), 1279–1290.
16. Salas-Salvadó, J., Bulló, M., Estruch, R., et al. Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial. Ann Intern Med 160 (2014), 1–10.
17. Esposito, K., Maiorino, M.I., Bellastella, G., Chiodini, P., Panagiotakos, D., Giugliano, D., A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses. BMJ Open, 5, 2015, e008222.
18. Sacks, F.M., Carey, V.J., Anderson, C.A.M., et al. Effects of high vs low glycemic index of dietary carbohydrate on cardiovascular disease risk factors and insulin sensitivity: the OmniCarb randomized clinical trial. JAMA 312 (2014), 2531–2541.
19. Balducci, S., Zanuso, S., Nicolucci, A., et al. Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES). Arch Intern Med 170 (2010), 1794–1803.
20. Jensen, M.D., Ryan, D.H., Apovian, C.M., et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 63:Pt B (2014), 2985–3023.
21. Clair, C., Rigotti, N.A., Porneala, B., et al. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA 309 (2013), 1014–1021.
22. Griffin, S.J., Borch-Johnsen, K., Davies, M.J., et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 378 (2011), 156–167.
23. Rajpathak, S.N., Aggarwal, V., Hu, F.B., Multifactorial intervention to reduce cardiovascular events in type 2 diabetes. Curr Diab Rep 10 (2010), 16–23.
24. Antithrombotic Trialists' (ATT) Collaboration, Baigent, C., Blackwell, L., Collins, R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (2009), 1849–1860.
25. Ogawa, H., Nakayama, M., Morimoto, T., et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300 (2008), 2134–2141.
26. Belch, J., MacCuish, A., Campbell, I., et al. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ, 337, 2008, a1840.
27. Kassoff, A., Buzney, S.M., McMeel, J.W., Weiter, J.J., Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study report 14. JAMA 268 (1992), 1292–1300.
28. De Berardis, G., Sacco, M., Strippoli, G.F.M., et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ, 339, 2009, b4531.
29. Calvin, A.D., Aggarwal, N.R., Murad, M.H., et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 32 (2009), 2300–2306.
30. Pignone, M., Alberts, M.J., Colwell, J.A., et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. J Am Coll Cardiol 55 (2010), 2878–2886.
31. Adler, A.I., Stratton, I.M., Neil, H.A.W., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321 (2000), 412–419.
32. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998), 703–713.
33. Hansson, L., Zanchetti, A., Carruthers, S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351 (1998), 1755–1762.
34. Patel, A. ADVANCE Collaborative Group, MacMahon, S., Neal, B., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007), 829–840.
35. Arguedas, J.A., Perez, M.I., Wright, J.M., Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev, 2009, CD004349.
36. ACCORD Study Group, Cushman, W.C., Evans, G.W., Byington, R.P., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1575–1585.
37. Estacio, R.O., Coll, J.R., Tran, Z.V., Schrier, R.W., Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens 19 (2006), 1241–1248.
38. Estacio, R.O., Jeffers, B.W., Hiatt, W.R., Biggerstaff, S.L., Gifford, N., Schrier, R.W., The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338 (1998), 645–652.
39. Schrier, R.W., Estacio, R.O., Esler, A., Mehler, P., Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61 (2002), 1086–1097.
40. Emdin, C.A., Rahimi, K., Neal, B., Callender, T., Perkovic, V., Patel, A., Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313 (2015), 603–615.
41. Brunström, M., Carlberg, B., Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ, 352, 2016, i717.
42. McBrien, K., Rabi, D.M., Campbell, N., et al. Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 172 (2012), 1296–1303.
43. James, P.A., Oparil, S., Carter, B.L., et al. 2014 evidence-based guideline for the management of high blood pressure in adults. JAMA, 311, 2014, 507.
44. Xie, X., Atkins, E., Lv, J., et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387 (2016), 435–443.
45. Daly, C.A., Fox, K.M., Remme, W.J., et al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 26 (2005), 1369–1378.
46. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355 (2000), 253–259.
47. Lindholm, L.H., Ibsen, H., Dahlöf, B., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002), 1004–1010.
48. Soran, H., Durrington, P.N., Susceptibility of LDL and its subfractions to glycation. Curr Opin Lipidol 22 (2011), 254–261.
49. Collins, R., Reith, C., Emberson, J., et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388 (2016), 2532–2561.
50. Shepherd, J., Barter, P., Carmena, R., et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29 (2006), 1220–1226.
51. Knopp, R.H., d'Emden, M., Smilde, J.G., Pocock, S.J., Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29 (2006), 1478–1485.
52. Colhoun, H.M., Betteridge, D.J., Durrington, P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004), 685–696.
53. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371 (2008), 117–125.
54. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63:Pt B (2014), 2889–2934.
55. ACCORD Study Group, Ginsberg, H.N., Elam, M.B., Lovato, L.C., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1563–1574.
56. Selvin, E., Marinopoulos, S., Berkenblit, G., et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141 (2004), 421–431.
57. Stratton, I.M., Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000), 405–412.
58. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
59. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993), 977–986.
60. Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A.W., 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
61. ADVANCE Collaborative Group, Patel, A., MacMahon, S., Chalmers, J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
62. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein, H.C., Miller, M.E., Byington, R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
63. Duckworth, W., Abraira, C., Moritz, T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009), 129–139.
64. Skyler, J.S., Bergenstal, R., Bonow, R.O., et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. Circulation 119 (2009), 351–357.
65. Riddle, M.C., Ambrosius, W.T., Brillon, D.J., et al. Epidemiologic relationships between a1c and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 33 (2010), 983–990.
66. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998), 854–865.
67. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
68. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
69. Marso, S.P., Bain, S.C., Consoli, A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
70. Perkovic, V., Rodgers, A., Redefining blood-pressure targets—SPRINT starts the marathon. N Engl J Med 373 (2015), 2175–2178.
71. de Ferranti, S.D., de Boer, I.H., Fonseca, V., et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care 37 (2014), 2843–2863.
72. Nathan, D.M., Cleary, P.A., Backlund, J.-Y.C., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005), 2643–2653.
73. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan, D.M., Zinman, B., et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 169 (2009), 1307–1316.